Trial Profile
Comparison of ultralongacting insulin, glargine and degludec in type2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary) ; Insulin aspart; Insulin glulisine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 16 Apr 2013 New trial record